Download and print
copies of clinical tools
Click here
Print out a brochure
for your patients with
Parkinson's disease*
Click here
*  You will need Adobe® Reader®  to download
this file. If you don't have
Adobe Reader, click here
for a free and secure
download.

FOR THE INITIAL AND LONG-TERM TREATMENT OF PARKINSON'S DISEASE (PD)

Drug-drug interactions are an important consideration in patients on multiple medications

  • MIRAPEX is not metabolized in the liver and is renally excreted
  • Absolute bioavailability is >90%, with 90% dose recovery (in urine), almost all as unchanged drug

An increasing number of Americans are on multiple medications28-30

 
 

Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease (PD).

Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur. In clinical trials for early PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea (28% vs. 18%), dizziness (25% vs. 24%), somnolence (22% vs. 9%), insomnia (17% vs. 12%), asthenia (14% vs. 12%), and constipation (14% vs. 6%). In clinical trials for advanced PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are postural hypotension (53% vs. 48%), dyskinesia (47% vs. 31%), extrapyramidal syndrome (28% vs. 26%), insomnia (27% vs. 22%), dizziness (26% vs. 25%), accidental injury (17% vs. 15%), hallucinations (17% vs. 4%), and dream abnormalities (11% vs. 10%).

Patients and caregivers should be informed that impulse control disorders and compulsive behaviors have been reported in patients taking dopamine agonists, including MIRAPEX.

Please see full Prescribing Information.

This information is intended for U.S. residents only.